<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR><BR>               <BR>               <BR>                  <BR>                     <BR>                        Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction (6.1).<BR><BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-545-5979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1 Clinical Trials Experience<BR><BR>                     <BR>                        The following serious adverse reactions are also discussed elsewhere in the labeling:<BR><BR>                        <BR>                           Bleeding [see Boxed Warning and Warnings and Precautions (5.1, 5.2)]<BR>                           <BR>                           Thrombotic thrombocytopenic purpura [see Warnings and Precautions (5.4)]<BR>                           <BR>                        <BR>                        Safety in patients with ACS undergoing PCI was evaluated in a clopidogrel-controlled study, TRITON-TIMI 38, in which 6741 patients were treated with Effient (60-mg loading dose and 10 mg once daily) for a median of 14.5 months (5802 patients were treated for over 6 months; 4136 patients were treated for more than 1 year). The population treated with Effient was 27 to 96 years of age, 25% female, and 92% Caucasian. All patients in the TRITON-TIMI 38 study were to receive aspirin. The dose of clopidogrel in this study was a 300-mg loading dose and 75 mg once daily.<BR><BR>                        Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared with the rates observed in other clinical trials of another drug and may not reflect the rates observed in practice.<BR><BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Drug Discontinuation<BR>                              <BR>                              The rate of study drug discontinuation because of adverse reactions was 7.2% for Effient and 6.3% for clopidogrel. Bleeding was the most common adverse reaction leading to study drug discontinuation for both drugs (2.5% for Effient and 1.4% for clopidogrel).<BR><BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Bleeding<BR>                              <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Bleeding Unrelated to CABG Surgery - In TRITON-TIMI 38, overall rates of TIMI Major or Minor bleeding adverse reactions unrelated to coronary artery bypass graft surgery (CABG) were significantly higher on Effient than on clopidogrel, as shown in Table 1.<BR><BR>                                    <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t1" width="100%"><BR>                                       <caption>Table&#160;1: Non-CABG-Related Bleeding<sup>a</sup> (TRITON-TIMI 38)<BR></caption><BR>                                       <col width="43.211%" align="left"/><BR>                                       <col width="22.081%" align="left"/><BR>                                       <col width="20.380%" align="left"/><BR>                                       <col width="14.329%" align="left"/><BR>                                       <tfoot><BR>                                          <tr><BR>                                             <td colspan="4" align="left" valign="top"><BR>                                                <paragraph styleCode="footnote"><BR>                                                   <sup>a</sup> Patients may be counted in more than one row.<br/><BR>                                                   <sup>b</sup> See 5.1 for definition.<BR></paragraph><BR>                                             </td><BR>                                          </tr><BR>                                       </tfoot><BR>                                       <tbody><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">Effient</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(%)</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(N=6741)</content><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">Clopidogrel</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(%)</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(N=6716)</content><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">p-value</content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">TIMI Major or Minor bleeding<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.5<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.4<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">p=0.002<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">TIMI Major bleeding<sup>b</sup><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.2<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.7<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">p=0.029<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160;Life-threatening<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">p=0.015<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; Fatal<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.1<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;     Symptomatic intracranial hemorrhage (ICH)<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; Requiring inotropes<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.1<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;  Requiring surgical intervention<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;  Requiring transfusion&#160;(&#8805;4&#160;units)<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.7<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.5<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"/><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">TIMI Minor bleeding<sup>b</sup><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.4<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.9<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">p=0.022<BR></td><BR>                                          </tr><BR>                                       </tbody><BR>                                    </table><BR>                                    <BR><BR><BR><BR>                                       Figure 1 demonstrates non-CABG related TIMI Major or Minor bleeding. The bleeding rate is highest initially, as shown in Figure 1 (inset: Days 0 to 7) [see Warnings and Precautions (5.1)].<BR><BR>                                    Bleeding rates in patients with the risk factors of age ≥75 years and weight <60 kg are shown in Table 2.<BR><BR>                                    <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t2" width="100%"><BR>                                       <caption>Table 2: Bleeding Rates for Non-CABG-Related Bleeding by Weight and Age (TRITON-TIMI 38)<BR></caption><BR>                                       <col width="46.600%" align="left"/><BR>                                       <col width="13.620%" align="left"/><BR>                                       <col width="13.620%" align="left"/><BR>                                       <col width="13.620%" align="left"/><BR>                                       <col width="12.540%" align="left"/><BR>                                       <tbody><BR>                                          <tr><BR>                                             <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">Major/Minor</content><BR>                                             </td><BR>                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">Fatal</content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                                <content styleCode="bold">Effient</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(%)</content><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                                <content styleCode="bold">Clopidogrel</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(%)</content><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                                <content styleCode="bold">Effient</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(%)</content><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                                <content styleCode="bold">Clopidogrel</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(%)</content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Weight &lt;60 kg (N=308 Effient, N=356 clopidogrel)<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">10.1<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">6.5<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.0<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Weight &#8805;60 kg (N=6373 Effient, N=6299 clopidogrel)<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.2<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.1<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Age &lt;75 years (N=5850 Effient, N=5822 clopidogrel)<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.8<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.9<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.2<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.1<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Age &#8805;75 years (N=891 Effient, N=894 clopidogrel)<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">9.0<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">6.9<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.0<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.1<BR></td><BR>                                          </tr><BR>                                       </tbody><BR>                                    </table><BR>                                 <BR><BR><BR><BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Bleeding Related to CABG - In TRITON-TIMI 38, 437 patients who received a thienopyridine underwent CABG during the course of the study. The rate of CABG-related TIMI Major or Minor bleeding was 14.1% for the Effient group and 4.5% in the clopidogrel group (see <BR>                                       Table 3). The higher risk for bleeding adverse reactions in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.<BR><BR>                                    <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t3" width="100%"><BR>                                       <caption>Table&#160;3: CABG-Related Bleeding<sup>a</sup> (TRITON-TIMI 38)<BR></caption><BR>                                       <col width="39.800%" align="left"/><BR>                                       <col width="28.900%" align="left"/><BR>                                       <col width="31.300%" align="left"/><BR>                                       <tfoot><BR>                                          <tr><BR>                                             <td colspan="3" align="left" valign="top"><BR>                                                <paragraph styleCode="footnote"><BR>                                                   <sup>a</sup> Patients may be counted in more than one row.<BR></paragraph><BR>                                             </td><BR>                                          </tr><BR>                                       </tfoot><BR>                                       <tbody><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">Effient (%)</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(N=213)</content><BR>                                             </td><BR>                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                                <content styleCode="bold">Clopidogrel (%)</content><BR>                                                <br/><BR>                                                <content styleCode="bold">(N=224)</content><BR>                                             </td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">TIMI Major or Minor bleeding<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">14.1<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.5<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">TIMI Major bleeding<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">11.3<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.6<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; Fatal<BR></td><BR>                                             <td align="center" valign="bottom" styleCode="Botrule Rrule">0.9<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; Reoperation<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.8<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.5<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; Transfusion of &#8805;5 units<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">6.6<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.2<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; Intracranial hemorrhage<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0<BR></td><BR>                                          </tr><BR>                                          <tr><BR>                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">TIMI Minor bleeding<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.8<BR></td><BR>                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9<BR></td><BR>                                          </tr><BR>                                       </tbody><BR>                                    </table><BR>                                 <BR><BR><BR><BR>                                 <BR>                              <BR>                           <BR>                           <BR>                              <BR>                                 <BR>                                 <BR>                                 <BR>                                    <BR>                                       Bleeding Reported as Adverse Reactions - Hemorrhagic events reported as adverse reactions in TRITON-TIMI 38 were, for Effient and clopidogrel, respectively: epistaxis (6.2%, 3.3%), gastrointestinal hemorrhage (1.5%, 1.0%), hemoptysis (0.6%, 0.5%), subcutaneous hematoma (0.5%, 0.2%), post-procedural hemorrhage (0.5%, 0.2%), retroperitoneal hemorrhage (0.3%, 0.2%), pericardial effusion/hemorrhage/tamponade (0.3%, 0.2%), and retinal hemorrhage (0.0%, 0.1%).<BR><BR>                                 <BR>                                 <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Malignancies<BR>                              <BR>                              During TRITON-TIMI 38, newly-diagnosed malignancies were reported in 1.6% and 1.2% of patients treated with prasugrel and clopidogrel, respectively. The sites contributing to the differences were primarily colon and lung. It is unclear if these observations are causally-related or are random occurrences.<BR><BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Other Adverse Events<BR>                              <BR>                              In TRITON-TIMI 38, common and other important non-hemorrhagic adverse events were, for Effient and clopidogrel, respectively: severe thrombocytopenia (0.06%, 0.04%), anemia (2.2%, 2.0%), abnormal hepatic function (0.22%, 0.27%), allergic reactions (0.36%, 0.36%), and angioedema (0.06%, 0.04%). Table 4 summarizes the adverse events reported by at least 2.5% of patients.<BR><BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="t4" width="100%"><BR>                                 <caption>Table 4: Non-Hemorrhagic Treatment Emergent Adverse Events Reported by at Least 2.5% of Patients in Either Group<BR></caption><BR>                                 <col width="46.600%" align="left"/><BR>                                 <col width="27.200%" align="left"/><BR>                                 <col width="26.200%" align="left"/><BR>                                 <tbody><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><BR>                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                          <content styleCode="bold">Effient (%)</content><BR>                                          <br/><BR>                                          <content styleCode="bold">(N=6741)</content><BR>                                       </td><BR>                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule"><BR>                                          <content styleCode="bold">Clopidogrel (%)</content><BR>                                          <br/><BR>                                          <content styleCode="bold">(N=6716)</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypertension<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.5<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.1<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypercholesterolemia/Hyperlipidemia<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.0<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">7.4<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">5.5<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">5.3<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Back pain<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">5.0<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.5<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspnea<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.9<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.5<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.6<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.3<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dizziness<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.1<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.6<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Cough<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.9<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.1<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypotension<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.9<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.8<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fatigue<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.7<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4.8<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Non-cardiac chest pain<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.1<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.5<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Atrial fibrillation<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.9<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.1<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Bradycardia<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.9<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.4<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Leukopenia (&lt;4 x 10<sup>9</sup> WBC/L)<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.8<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.5<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Rash<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.8<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.4<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pyrexia<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.7<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.2<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Peripheral edema<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.7<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3.0<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pain in extremity<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.6<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.6<BR></td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.3<BR></td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">2.6<BR></td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2 Postmarketing Experience<BR><BR>                     <BR>                        The following adverse reactions have been identified during post approval use of Effient. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<BR><BR>                        <BR>                           Blood and lymphatic system disorders — Thrombocytopenia, Thrombotic thrombocytopenic purpura (TTP) [see Warnings and Precautions (5.4) and Patient Counseling Information (17.3)]<BR>                        <BR>                        <BR>                           Immune system disorders — Hypersensitivity reactions including anaphylaxis [see Contraindications (4.3)]<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>